Description

KEYTRUDA (pembrolizumab) developed by Merck & Co., Inc is an anti-PD-1 therapy that has been approved in over 40 indications in the U.S., including 18 tumor types and 2 tumor-agnostic indications, and has similarly been approved in markets worldwide for many of these indications. KEYTRUDA is not chemotherapy or radiation therapy it is an immunotherapy and it works with your immune system to help fight cancer. Immunotherapies such as KEYTRUDA may stop cancer cells from hiding. KEYTRUDA may enable T cells to find and attack cancer cells. This helps your immune system do what is designed to do: detect and fight cancer.

Keytruda has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors (including MSI-H/dMMR colorectal cancer and endometrial carcinoma), non-small-cell lung cancer (NSCLC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) solid tumors, and urothelial cancer including non-muscle invasive bladder cancer.

Keytruda is also approved as monotherapy for the adjuvant treatment of certain patients with melanoma, and for certain patients with renal cell carcinoma (RCC) post-surgery.

Keytruda is approved for adjuvant treatment following resection and platinum-based chemotherapy for certain patients with NSCLC.

Additionally, Keytruda is approved for patients with certain types of resectable NSCLC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

Keytruda is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

In addition, Keytruda is approved in combination with chemotherapy for the treatment of certain patients with advanced NSCLC, advanced malignant pleural mesothelioma, HNSCC, advanced biliary tract cancer, advanced esophageal cancer, advanced TNBC, and advanced or recurrent endometrial carcinoma; in combination with chemotherapy with or without bevacizumab, and in combination with chemoradiotherapy, for the treatment of certain patients with advanced cervical cancer; in combination with trastuzumab and chemotherapy for the treatment of certain patients with advanced human epidermal growth factor receptor 2 (HER2)-positive gastric or GEJ adenocarcinoma with programmed death-ligand 1 (PD-L1) (CPS 1), and in combination with chemotherapy for the treatment of certain patients with advanced HER2-negative gastric or GEJ adenocarcinoma; in combination with axitinib for the treatment of certain patients with advanced RCC; in combination with Lenvima (lenvatinib) for the treatment of certain patients with advanced RCC or advanced endometrial carcinoma; and in combination with enfortumab vedotin for certain patients with locally advanced or 

Revenue (2024):

• Keytruda is not only Merck & Co. top product, but also the best-selling drug worldwide In 2024, Sales of Keytruda ($29.482 billion) represented 46% of the Company's total sales.
• Global sales of Keytruda grew 18% in 2024, or 22% excluding the unfavorable effect of foreign exchange. The negative impact of foreign exchange was primarily due to the devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market.
• Keytruda sales growth in the U.S.A ($17.872 billion) reflects higher demand across the multiple approved metastatic indications, in particular for the treatment of certain types of bladder, endometrial, microsatellite instability-high (MSI-H) and renal cell cancers, as well as increased uptake across earlier-stage indications, including in certain types of high-risk early-stage triple-negative breast cancer (TNBC), NSCLC and RCC, and higher pricing.
• Keytruda sales growth in international markets ($11.610 billion) reflects higher demand predominately for the TNBC, melanoma and RCC earlier-stage indications, as well as uptake in cervical, gastric and renal cell cancer metastatic indications.
• The Company expects that the 2025 launch and reimbursement of new indications for Keytruda in the EU will have a negative impact on pricing in those markets.

Expiration Dates:

• Year of Expiration (U.S.): 2028
• Year of Expiration (EU): 2031
• Year of Expiration (Japan): 2032-2033
• Year of Expiration (China): 2028

Keytruda Cost:

• The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $11,795.44. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $23,590.88

Description

DARZALEX® (daratumumab) - Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize DARZALEX. DARZALEX is a prescription medicine used to treat adults with Multiple Myeloma. DARZALEX has established its position as a leading treatment option for Multiple Myeloma (blockbuster multiple myeloma treatment). 

Revenue (2024): Genmab receives royalties on worldwide net sales from Johnson & Johnson 

• Sales of Johnson & Johnson’s largest product, collectively DARZALEX (daratumumab) and subcutaneous (SC) product DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 13.1% of the Company's total revenues for fiscal 2024
• DARZALEX sales increased by 19.8%. $11.670 billion (2023: $9.744 billion) driven by continued share gains and market growth
• In the United States, sales of DARZALEX increased by 24.8 % $6.588 billion (2023: $5.277 billion)

Forecast: 

Johnson & Johnson aims to grow oncology sales to $50 billion by 2030. DARZALEX is expected to reach sales of around $16.4 billion in 2030. 

Expiration Dates: Genmab A/S owns two patent families related to DARZALEX, and Janssen Biotech, Inc. has an exclusive license to those patent families. Janssen Biotech, Inc. owns a separate patent portfolio related to DARZALEX FASPRO. 

• Year of Expiration (U.S): 2029
• Year of Expiration (EU): compound/use patent protection in select countries extends to 2031/2032
• Year of Expiration (Japan): 2030

DARZALEX® Cost:

• The list (or wholesale) price for DARZALEX Ivin United States is around $788.85 (5 millilitres) & Darzalex Faspro in United States is $10,122 - $10,828 / 1800 mg vial. The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less

Description

TAGRISSO® (osimertinib)- a multiblockbuster drug developed by AstraZeneca is a prescription medicine approved in 112 countries for adjuvant early-stage EGFRm non-small cell lung cancer and in 113 countries for 1st- and 2nd-line treatment of advanced EGFRm non-small cell lung cancer. Approved in combination with chemotherapy in 1st-line advanced EGFRm non-small cell lung cancer in 27 countries and in several countries as a maintenance treatment after definitive chemoradiation in unresectable Stage III EGFRm non-small cell lung cancer. 

Revenue (2024): 

• Worldwide Oncology sales were $22.353 billion* in 2024, an increase of 21% (24% at CER) compared with 2023 ($18.447 billion*)
• TAGRISSO Global sales increased by 13% $6.580 billion (2023: $ 5.799 billion) driven by a strong global demand in adjuvant and 1st-line settings
• In the United States, sales of TAGRISSO were $2.763 billion in 2024 (2023: $2.276 billion) 

*Total Revenue - the sum of product sales, collaboration revenue and alliance revenue.

Forecast: 

AstraZeneca aims for >50% of lung cancer patients to be eligible for AZN medicine by 2030. Establishing Tagrisso as backbone TKI in EGFRm. Market leader in 1L, sustained FLAURA-2 growth.

Continued early-stage adoption with ADAURA, LAURA. TAGRISSO is expected to reach sales of around $8.55 billion in 2030. 

Expiration Dates:

• Year of Expiration (U.S): 2032
• Year of Expiration (EU): 2032
• Year of Expiration (Japan): 2032

 TAGRISSO® Cost:

• The list (or Average wholesale) price for TAGRISSO 40mg Tablet is around $608.34 (UNIT PRICE). The prices listed is the Average Wholesale Price ("AWP") as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed. Price listed is for the lowest dosage.

Description

OPDIVO® (nivolumab)- jointly developed and commercialized by Bristol-Myers Squibb & ONO PHARMACEUTICAL is a biological product and a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells. 

It has been approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer. The Opdivo+Yervoy regimen also is approved in multiple markets for the treatment of NSCLC, melanoma, MPM, RCC, CRC and various gastric and esophageal cancers. The list (wholesale acquisition cost) price for OPDIVO® (nivolumab) 40 mg/4 mL (VIAL (ML)) is $1,323.85. & 240 mg/24 mL (VIAL (ML)) is $7,943.08. The prices patients pay at the pharmacy may be different and largely depend on the out-of-pocket costs set by their insurance provider, pharmacy charges, and/or discounts or financial assistance that may be available to the patient.

Revenue (2024): BMS is the principal in the end customer product sales and has the exclusive right to develop, manufacture and commercialize Opdivo worldwide except in Japan, South Korea and Taiwan. Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries (Japan, South Korea and Taiwan).

• In fiscal year 2024, OPDIVO Global sales were around $10.14 billion. BMS reported revenue of $9.3 billion in 2024 (US: $5.35 billion; Non-US: $3.95 billion). ONO Pharma reported revenue of 126.6 billion of Yen (~ $835 million) from 1st January 2024 to 31st December 2024.
• U.S. revenues increased 2% in 2024 primarily due to higher average net selling prices, partially offset by lower demand.
• Non-US revenues increased 5% in 2024 primarily due to higher demand for core indications and additional indication launches and higher average net selling prices, partially offset by foreign exchange impact of 9%. Excluding foreign exchange impacts, revenues increased 14%.
• Opdivo Sales Mix (United States): ~28% non-small cell lung cancer; ~ 23% Renal cell carcinoma; ~22% Melanoma, ~27% Upper gastrointestinal (GI)/bladder

Forecast: 

OPDIVO is expected to reach worldwide sales of around $11 billion in 2028 & and will see a sharp decline after 2028 due to biosimilar/generic competition in US (major market). 2029: ~$8.2B & 2030: ~$7.0B 

Expiration Dates: Opdivo (nivolumab):

• Year of Expiration (U.S): 2028
• Year of Expiration (EU): 2030
• Year of Expiration (Japan): 2031

OPDIVO ® Cost:

• The list (wholesale acquisition cost) price for OPDIVO® (nivolumab) 40 mg/4 mL (VIAL (ML)) is $1,323.85. & 240 mg/24 mL (VIAL (ML)) is $7,943.08. The prices patients pay at the pharmacy may be different and largely depend on the out-of-pocket costs set by their insurance provider, pharmacy charges, and/or discounts or financial assistance that may be available to the patient.

Description

VERZENIO® (abemaciclib) - CDK4/6 market leader developed by Eli Lilly and Company, is a prescription medicine used to treat certain types of breast cancer known as HR+/HER2– (hormone receptor positive/human epidermal growth factor receptor 2 negative) breast cancer. 

Revenue (2024):

• Worldwide Oncology sales were $8.752 billion in 2024, an increase of 31.45% compared with 2023 ($6.658 billion)
• VERZENIO Global sales increased by 37% $5.306 billion (2023: $3.863 billion).
• In the United States, sales of VERZENIO were $3.420.6 billion in 2024 (2023: $ 2.509 billion) an increase of 36 percent in the U.S., driven by increased demand, wholesaler buying
• patterns and, to a lesser extent, higher realized prices.
• Verzenio® has strong market penetration in the U.S., with nearly 60% of high-risk early breast cancer patients receiving Verzenio®.

 Forecast: 

VERZENIO is expected to reach sales of around $12 billion in 2030. 

Expiration Dates:

• Year of Expiration (U.S): 2031
• Year of Expiration (EU): 2033
• Year of Expiration (Japan): 2034 

VERZENIO ® Cost:

• The list (wholesale acquisition cost) price for VERZENIO $16,330.08 per month. A monthly supply of Verzenio is defined as 28-day supply. The prices patients pay at the pharmacy may be different and largely depend on the out-of-pocket costs set by their insurance provider, pharmacy charges, and/or discounts or financial assistance that may be available to the patient.

Description

IMFINZI® (durvalumab) a multiblockbuster drug developed by AstraZeneca is a prescription medicine approved in 97 countries in the curative-intent setting of unresectable, Stage III NSCLC and in 63 countries for metastatic NSCLC. Approved in nine countries for resectable NSCLC. Approved in 97 countries for extensive-stage SCLC and in three countries including the US for limited-stage SCLC.Approved in 89 countries for locally advanced or metastatic Biliary tract cancer (BTC). Approved in 71 countries in combination with Imjudo for uHCC and 33 countries as monotherapy. Approved in 36 countries for advanced or recurrent endometrial cancer. Since its first approval, more than 374,000 patients have been treated with Imfinzi and it’s the only approved immunotherapy in limited-stage SCLC and the global SoC in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not progressed after CRT.

Revenue (2024):

• Worldwide Oncology sales were $22.353 billion in 2024, an increase of 21% (24% at CER) compared with 2023 ($18.447 billion). Commercial delivery and sales performance driven by five multiblockbuster medicines in 2024: Tagrisso ($6.580 billion), Imfinzi ($4.717 billion), Calquence ($3.129 billion), Lynparza ($3.672 billion) and Enhertu ($1.982 billion). Worldwide Oncology Product sales were $20.275 billion in 2024.
• Imfinzi Product Sales ($4.717 billion) grew by 17% (CER: 21%) due to growing demand. (2023: $4.019 billion)

Forecast:

• AstraZeneca aims for >50% of lung cancer patients to be eligible for AZN medicine by 2030.
• Imfinzi – growth momentum to accelerate with multiple new indication opportunities in 2025. Lung | early-stage NSCLC and LS-SCLC; GI | build on momentum; GU | multiple bladder opportunities.
• Imfinzi is expected to reach worldwide sales of ~$5.9 billion in 2025 and ~$8.75 billion in 2030.
  
  

Expiration Dates: IMFINZI (durvalumab)

• Year of Expiration (U.S): 2031
• Year of Expiration (EU): 2030
• Year of Expiration (Japan): 2033

IMFINZI ® Cost:

• The list (wholesale acquisition cost) price for IMFINZI® (durvalumab) IMFINZI 120 MG/2.4 ML VIAL is $483.26. The price shown is for the lowest dosage. The prices patients pay at the pharmacy may be different and largely depend on the out-of-pocket costs set by their insurance provider, pharmacy charges, and/or discounts or financial assistance that may be available to the patient.